Journals A-Z
All Subjects
Free Journals
sciepub.com
American Journal of Cardiovascular Disease Research
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: https://www.sciepub.com/journal/ajcdr Editor-in-chief: Dario Galante
Open Access
Journal Browser
Go
Issue 1, Volume 2
Article Metrics
  • 18761
    Views
  • 13330
    Saves
  • 0
    Citations
  • 42
    Likes
Export Article
American Journal of Cardiovascular Disease Research. 2014, 2(1), 9-16
DOI: 10.12691/ajcdr-2-1-3
Open AccessReview Article

The Role of Calcium-Sensitizer Levosimendan for the Treatment of Heart Failure

Mohammad Asif1,

1Department of Pharmacy, GRD (PG) IMT, Dehradun, (Uttarakhand), India

Pub. Date: March 12, 2014
View Full Text Full Text PDF (160 KB) Full Text ePUB(44 KB)

Cite this paper:
Mohammad Asif. The Role of Calcium-Sensitizer Levosimendan for the Treatment of Heart Failure. American Journal of Cardiovascular Disease Research. 2014; 2(1):9-16. doi: 10.12691/ajcdr-2-1-3

Abstract

In the treatment of heart failure, clinical signs are low cardiac output, therapy with positive inotropic agents in an acute cardiac care is mandatory. Three classes of inotropic drugs are currently used, including beta-adrenergic agonists (especially dobutamine), phosphodiesterase inhibitors (such as milrinone) and the recently developed calcium sensitizers such as levosimendan. The classic inotropic drugs offer short-term haemodynamic enhancement in heart failure patient and their use has been connected with poor prognosis. The inotropic drugs, the Ca2+-sensitizers, may offer a choice of long-lasting result.

Keywords:
inotropic agents heart failure calcium-sensitizers

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Sakata Y. Clinical significance of calcium sensitizer. Clin Calcium. 2013; 23 (4): 575-82.
 
[2]  Arai M. Calcium mobilizers and calcium sensitizers. Nihon Rinsho. 2011; 69 Suppl 9: 417-22.
 
[3]  Giglioli C, Cecchi E, Landi D, Chiostri M, Spini V, Valente S, Gensini GF, Romano SM. Levosimendan produces an additional clinical and hemodynamic benefit in patients with decompensated heart failure successfully submitted to a fluid removal treatment. Congest Heart Fail. 2012; 18 (1): 47-53.
 
[4]  van Hees HW, Andrade Acuña G, Linkels M, Dekhuijzen PN, Heunks LM. Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure. Br J Pharmacol. 2011; 162 (3): 566-73.
 
[5]  Robertson IM, Sun YB, Li MX, Sykes BD. A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex. J Mol Cell Cardiol. 2010; 49 (6): 1031-41.
 
[6]  Follath F. Newer treatments for decompensated heart failure: focus on levosimendan. Drug Des Devel Ther. 2009; 3:73-8.
 
[7]  Meyer K, Klocke RC, Schipke JD, Gams E, Korbmacher B. Ca2+ sensitizer superior to catecholamine during myocardial stunning? Eur J Cardiothorac Surg. 2008; 34 (2): 326-31.
 
[8]  Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs. 2008; 17 (8): 1143-50.
 
[9]  Endoh M. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure? Br J Pharmacol. 2007; 150 (7): 826-8. Epub 2007 Feb 26.
 
[10]  Endoh M. Cardiac Ca2+ signaling and Ca2+ sensitizers. Circ J. 2008; 72 (12): 1915-25.
 
[11]  Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther. 2007; 114 (2): 184-97.
 
[12]  Kasikcioglu HA, Uyarel H, Tartan Z, Kasikcioglu E, Ozturk R, Cam N. Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure? Int J Cardiol. 2007; 118 (2): 246-8. Epub 2006 Sep 28.
 
[13]  Papp JG, Pollesello P, Varró AF, Végh AS. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther. 2006; 11 (2): 129-35.
 
[14]  González-Chon O, García López SM, Chacón Mercado MA, Arias Sánchez EA, Vega Zapata RE. Levosimendan: a new strategy in the treatment of heart failure. Arch Cardiol Mex. 2005; 75 Suppl 3: S3-130-9.
 
[15]  Perrone SV, Kaplinsky EJ. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol. 2005; 103 (3): 248-55.
 
[16]  Haikala H, Pollesello P. Calcium sensitivity enhancers. IDrugs. 2000; 3 (10): 1199-205.
 
[17]  Bonnefoy E, Trindade PT. Levosimendan, a revolution in the world of inotropic agents. Rev Med Suisse. 2005; 1 (21): 1425-6, 1428-9.
 
[18]  Andersen GO, Eritsland J, Bjørnerheim R, Kløw NE, Jonassen A, Mangschau A. Cardiogenic shock-new therapeutic strategies. Tidsskr nor Laegeforen. 2005; 125 (10): 1318-21.
 
[19]  Ng TM.Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy. 2004; 24 (10): 1366-84.
 
[20]  Papp Z, Van Der Velden J, Borbély A, Edes I, Stienen GJ. Effects of Ca2+-sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts. J Muscle Res Cell Motil. 2004; 25 (3): 219-24.
 
[21]  Sorsa T, Pollesello P, Rosevear PR, Drakenberg T, Kilpeläinen I. Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. Eur J Pharmacol. 2004; 486 (1): 1-8.
 
[22]  Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J. 2003; 4 Suppl 2: 34S-38S.
 
[23]  Erhardt LR. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure? Ital Heart J. 2003; 4 Suppl 2: 27S-33S.
 
[24]  Lehmann A, Boldt J, Kirchner J. The role of Ca2+-sensitizers for the treatment of heart failure. Curr Opin Crit Care. 2003; 9 (5): 337-44.
 
[25]  Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002; 40 (3): 323-38.
 
[26]  Teerlink JR. The development of new medical treatments for acute decompensated heart failure. Heart Fail Monit. 2002; 2 (4): 129-37.
 
[27]  Nawarskas JJ, Anderson JR. Levosimendan: a unique approach to the treatment of heart failure. Heart Dis. 2002; 4(4):265-71.
 
[28]  Endoh M. Mechanism of action of Ca2+ sensitizers--update 2001. Cardiovasc Drugs Ther. 2001; 15 (5): 397-403.
 
[29]  Kleerekoper Q, Putkey JA. Drug binding to cardiac troponin C. J Biol Chem. 1999 Aug 20; 274 (34): 23932-9.
 
[30]  Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999; 288 (1): 316-25.
 
[31]  Zimmermann N, Boknik P, Gams E, Herzig JW, Neumann J, Scholz H. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Eur J Cardiothorac Surg. 1998; 14 (1): 70-5.
 
[32]  Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995; 27 (9): 1859-66.
 
[33]  Haikala H, Levijoki J, Lindén IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol. 1995; 27 (10): 2155-65.
 
[34]  Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol. 1995; 26 Suppl 1: S10-9.
 
[35]  Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Lindén IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995; 25 (5): 794-801.
 
[36]  Nielsen-Kudsk JE, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol. 1995; 26 Suppl 1: S77-84.
 
[37]  Lehtonen L, Mills-Owens P, Akkila J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol. 1995; 26 Suppl 1: S70-6.
 
[38]  Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol. 1995; 26 Suppl 1: S45-51.
 
[39]  Varro A, Papp JG. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers is placed? J Cardiovasc Pharmacol. 1995; 26 Suppl 1: S32-44.
 
[40]  Rusca M, Liaudet L. Inotropic agents for treatment of acute heart failure syndromes in intensive care. Rev Med Suisse. 2009; 5 (229): 2512-5.
 
Manuscript template